LILRB2 promotes immune escape in breast cancer cells via enhanced HLA-A degradation.

Zhiyuan JiangQianru HuangYujie ChangYiran QiuHao ChengMengdi YangShunyi RuanSuyuan JiJing SunZhiyu WangShengyuan XuRui LiangXueyu DaiKejin WuBin LiDan LiHui Zhao

Published in: Cellular oncology (Dordrecht) (2024)

LILRB2 downregulates HLA-A to promote immune evasion in BC cells and is a promising new target for BC treatment.

Keyphrases

breast cancer cells
induced apoptosis
cell cycle arrest
combination therapy
signaling pathway
cell proliferation